MimiVax Announces Positive Interim Results from Phase II

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
15
MimiVax Announces Positive Interim Results from Phase II Trial of SurVaxM Immunotherapy for the Treatment of Newly Diagnosed Glioblastoma
  • Interim analysis shows significant survival benefit compared to historical standard of care;
  • Combination of SurVaxM and standard therapy was well-tolerated, with few serious side effects;
  • MimiVax to share findings at ASCO annual meeting.

BUFFALO, N.Y., May 21, 2018 (GLOBE NEWSWIRE) -- MimiVax LLC, a clinical-stage biotechnology company developing immunotherapeutics and targeted therapies for cancer treatment, today announced positive interim results from a multicenter Phase II study of SurVaxM in patients with newly diagnosed glioblastoma (nGBM). These promising interim results support further development of SurVaxM in combination with standard therapy as a potential treatment for glioblastoma. A randomized trial of SurVaxM in glioblastoma is planned, pending completion of this study and review at the end of Q4 2018.

Key interim results include 91% of patients receiving SurVaxM in combination therapy achieving 12-month overall survival (OS-12), compared to 61% historical standard of care; 96% achieved six-month progression-free survival (PFS-6), compared to 54% historical standard of care. In this study, 13 of 63 patients continue to be without progression for over 12 months. Evidence to date shows that SurVaxM is easy to administer, safe, tolerable with few serious adverse effects.

The study is being conducted at five sites, namely Roswell Park Comprehensive Cancer Center, the Cleveland Clinic, Dana-Farber Cancer Institute, Massachusetts General Hospital and Beth Israel Deaconess Medical Center. MimiVax will present these findings at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

“These interim Phase II trial results in newly diagnosed glioblastoma patients are very promising and offer the potential for longer-term survival in this group where there is great unmet medical need. We believe this drug has the potential to change the glioblastoma treatment paradigm,” said the study’s senior author, SurVaxM co-inventor Robert Fenstermaker, MD , who is Chair of Neurosurgery at Roswell Park and Chief Medical Officer at MimiVax.

SurVaxM, which was invented at Roswell Park Comprehensive Cancer Center, targets a cell-survival protein called survivin that is present in 95% of patients with glioblastomas, and also in patients with many other cancers. SurVaxM has dual mechanisms of action to stimulate a patient’s T-cell immunity and unique antibody-directed inhibition of the survivin pathway to control tumor growth and prevent or delay tumor recurrence. SurVaxM has been awarded orphan drug designation by the U.S. Food and Drug Administration (FDA).

Co-inventor Michael Ciesielski, PhD , Assistant Professor of Neurosurgery at Roswell Park and Chief Executive Officer for MimiVax, commented: “Glioblastoma is one of the most common and aggressive forms of brain cancer, with few effective treatment options. That dire need underscores the importance of these promising interim results, as we seek to develop new and better therapies. And because survivin is present in a huge percentage of cancers in general, we expect that SurVaxM could have broad applicability in many cancers beyond glioblastoma.”

The interim analysis includes 63 patients with an age range from 20-82 years (median = 60), male:female = 32:23.

PFS-6 was 96.3% (+2.8, -10.3)(n = 55) measured from diagnosis. OS-12 was 90.9% (+6.1, -16.5)(n = 33) from diagnosis. The regimen was generally well-tolerated, and drug-related adverse events were mild. The drug was highly active in stimulating immunologic response against tumor cells and produced survivin-specific antibody (IgG) titers and CD8+ T-cell responses. The drug also has the capacity to stimulate immune helper cell support, which is important for robust and sustained antitumor CD8+ activity.

Study Design

The trial was designed to determine PFS-6, OS-12 and immunologic response in nGBM patients treated with concurrent temozolomide (TMZ) and radiation, followed by adjuvant TMZ and survivin-targeted immunization with SurVaxM.

The trial is a single-arm, multi-center Phase II trial conducted in 63 evaluable patients with nGBM.  Patients who underwent craniotomy with gross total resection, followed by chemoradiation, were eligible. SurVaxM is delivered through a non-invasive subcutaneous injection of four serial priming doses of SurVaxM (500 mcg) with Montanide and sargramostim (100 mcg) every two weeks, followed by standard adjuvant TMZ and maintenance SurVaxM every 12 weeks until progression. Endpoints were designed to determine PFS-6, OS-12 and immunologic response in nGBM patients treated with the survivin-targeted immunization SurVaxM. Interim data presented here and at ASCO was obtained as of February 2018 and final study data is expected in Q4 2018.

Research on SurVaxM has led to the development of additional platform agents, including a therapeutic anti-survivin monoclonal antibody and survivin-targeted CAR T cells, both of which are under development by scientists and clinicians at MimiVax and Roswell Park.

This Phase II study has been supported by donations from the Roswell Park Alliance Foundation and through private investment. Manmeet Ahluwalia, MD , of the Cleveland Clinic is lead principal investigator of the Phase II trial and first author of the study to be presented at ASCO 2018.

For more information about the Phase II clinical trial, call 1-800-ROSWELL (1-800-767-9355) or send an e-mail to  AskRoswell@Roswellpark.org . Additional details are available here .

About MimiVax LLC:

MimiVax LLC is a New York based private, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutics for cancer treatment. The Company was formed in 2012 to develop and commercialize its lead candidate SurVaxM. SurVaxM is currently undergoing Phase II study in glioblastoma and Phase I study in multiple myeloma. For more information on MimiVax, visit www.mimivax.com .

About SurVaxM:

SurVaxM is a first-in-class, patented peptide mimic immunogen that targets survivin, a cell-survival protein present in 95% of glioblastomas and in many other cancers as well. SurVaxM has simultaneous dual mechanisms to stimulate patients’ own T-cell immunity and unique antibody-directed inhibition of the survivin pathway to control tumor growth and prevent recurrence. SurVaxM has demonstrated safety and tolerability in a Phase I study in patients with recurrent or progressive malignant glioma (brain tumors). With support from Roswell Park and private investors, SurVaxM has entered a Phase II clinical trial in adults with newly diagnosed glioblastoma at leading cancer centers, including Roswell Park Comprehensive Cancer Center, the Cleveland Clinic, Dana-Farber Cancer Institute, Massachusetts General Hospital and Beth Israel Deaconess Medical Center. A Phase I clinical trial evaluating SurVaxM in combination with REVLIMID® (lenalidomide) as maintenance therapy for adults with multiple myeloma has also been initiated with support from Celgene (marketer of REVLIMID®). Because survivin is present in most cancers, including multiple myeloma, melanoma, ovarian, renal, lymphoma, prostate and breast cancers, SurVaxM could have applicability in other cancers.

About Glioblastoma:

Glioblastoma is the most common and aggressive form of primary brain cancer in adults. Nonetheless, it is still considered a rare disease, with around 14,000 new cases diagnosed annually. Median progression-free survival is around 7 months. With standard therapy (surgery followed by chemoradiation and then adjuvant chemotherapy), the median overall survival is only 15 months, with 3-5% of patients living 5 years. Although a large body of basic and clinical research has been devoted to improving treatment for this disease, survival has improved only modestly in the past several decades, leaving a substantial unmet medical need.

About Roswell Park:

Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at www.roswellpark.org , or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@roswellpark.org .

Media Contacts:

For MimiVax:

Peter Steinerman, for Affinity Growth Advisors

516-641-8959

peter.steinerman@affinitygrowth.com

Roswell Park Comprehensive Cancer Center:

Annie Deck-Miller

716-845-8593

annie.deck-miller@roswellpark.org

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dario’s Second Women’s Health Win Tests Expansion Case

Updated Category News Views 89

Midlife care just became the newest proving ground for DarioHealth’s sales pitch. The company says The Minnesota Star Tribune has expanded its existing relationship to include Dario Women™, a program for employees navigating perimenopause and menopause. Eligible employees are expected to gain access in January 2027. For NASDAQ:DRIO, this is not some grand revenue...

Continue Reading
Hyster-Yale's $125 Million Convertible Debt Shuffle

Updated Category News Views 142

Forklifts do not make headlines often, but debt terms sure can. Hyster-Yale has proposed a $125 million private offering of convertible senior notes due November 15, 2031, with buyers able to take another $18.75 million if the initial purchasers exercise their option. For NYSE:HY holders, this is not a victory lap or a distress flare by itself. It is a refinancing...

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 91

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
Miami Office Puts Dubai Closer to U.S. Business Deal Flow

Updated Category News Views 11

Miami is not a random pin on a map; it is a deliberate front door to the Americas, and Dubai International Chamber has decided it needs someone standing in it. The chamber opened a representative office there on November 19, 2026, its second in the United States after launching in New York during the Dubai Business Forum – USA in November 2025. This is not the sort of...

Continue Reading
Thanksgiving Dog Safety Is a Pet Care Reality Check

Updated Category News Views 103

A crowded Thanksgiving kitchen can turn a well-behaved dog into a scavenger with lousy odds. Camp Bow Wow’s holiday guidance is not pretending the meal itself is the problem; the trouble is that a house full of distracted people, rich food and unsecured trash creates a pile of easy mistakes. For pet owners, that is a fair reminder. For anybody watching the pet-care...

Continue Reading
Happiest Minds Extends Absa Banking Platform Reach

Updated Category News Views 34

Mauritius just handed Happiest Minds a useful, if modest, banking-tech scorecard. On November 19, 2026, the company said its cloud-native Arttha platform had been deployed to support selected capabilities within Spark by Absa, a digital banking and lifestyle app from Absa Bank (Mauritius). This is not the sort of announcement that lets anybody pencil in a giant revenue...

Continue Reading
Marina del Rey's Travel Award Brings Fresh Attention

Updated Category News Views 86

A harbor town just got handed a useful little megaphone. On November 18, 2026, the Marina del Rey Tourism Board said Marina del Rey had been selected as a winner in Good Housekeeping's 2027 Travel Awards. That is not a quarterly earnings event, and nobody ought to dress it up as one. Still, in the visitor economy, recognition from a broad consumer publication can matter...

Continue Reading
Valley Family Health Breach Notice Raises Hard Questions

Updated Category News Views 68

Seven months is a long time for sensitive patient data to sit inside an unresolved security story. Valley Family Health Care, Inc. says it suffered a network disruption on or about March 13, 2026, investigated with outside cybersecurity specialists, and ultimately determined that an unauthorized actor accessed and acquired certain files. The formal notification process...

Continue Reading
CHN Energy's Indonesia Record Deserves a Hard Look

Updated Category News Views 5

Twenty years of boots sinking into swamp mud tells a sturdier story than a polished anniversary slogan. CHN Energy says it entered Indonesia's energy market two decades ago and has since built an operating presence around reliable electricity, local training and community work. In a country scattered across thousands of islands, dependable power is not some decorative...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 229

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading

Top 5 Most Recently Viewed Articles

Stock Market Sees Notable Gains with Various Companies Rising

Updated Category News Views 165

U.S. Stocks Surge With Promising Developments The U.S. stock market experienced a significant uptick recently, highlighted by the Dow Jones index increasing over 200 points. This positive momentum was driven by various companies showcasing impressive stock gains during the trading day. Olo Inc.: A Leap Forward Olo Inc. (NYSE: OLO) garnered considerable attention as its...

Continue Reading
CACI International Welcomes New Board Member Scott Morrison

Updated Category News Views 220

Scott C. Morrison Joins CACI International's Board CACI International Inc (NYSE: CACI) has recently announced that Scott C. Morrison has joined its Board of Directors. This strategic appointment is effective immediately and highlights CACI's commitment to enhancing its leadership with experienced professionals. Morrison, recognized for his vast financial expertise, will...

Continue Reading
Frontera Energy's Q2 Report: Key Insights and Figures

Updated Category News Views 235

Frontera Energy Reports Second Quarter 2025 Results Key Financial Highlights: Frontera Energy Corporation (TSX: FEC) has reported significant financial outcomes for the second quarter of 2025. The company recorded a net loss of $455.2 million, primarily due to non-cash impairment charges tied to its interests in various assets. Despite the challenges, total production...

Continue Reading
Investigation Launched for Bank of Montreal Investors' Rights

Updated Category News Views 57

Bank of Montreal Investors Under Review Pomerantz LLP has initiated an investigation focused on potential claims that may impact investors of Bank of Montreal, recognized by its stock symbol BMO (NYSE: BMO). The firm is urging individuals who have invested in the company to come forward and discuss their concerns. With a commitment to protecting investor rights, Pomerantz...

Continue Reading
Hard Rock International and Seminole Gaming's Ocean Initiative

Updated Category News Views 240

Hard Rock International and Seminole Gaming Unite for Sustainability A global effort resulted in the collection of over 6,400 lbs. of waste, engaging more than 1,700 participants from various countries and communities. This initiative illustrates the commitment of Hard Rock International and Seminole Gaming to environmental stewardship through the Global Sound Waves...

Continue Reading